Nanoparticles Feature Two Mechanisms to Boost Effectiveness of Immunotherapy to Fight Cancer

Nanoparticles Feature Two Mechanisms to Boost Effectiveness of Immunotherapy to Fight Cancer

Image via ACS Nano Immunotherapy techniques for fighting cancer generally fall into two categories: preventing tumor cells from evading the immune system’s T cells and summoning T cells to attack the tumors. Now scientists at Johns Hopkins University School of Medicine have developed nanoparticles that perform both tasks at the same time, significantly improving the effectiveness of immunotherapy in a study on laboratory mice. The nanoparticles carry one antibody that blocks an inhibitory signal that helps tumors hide from the immune system, and a second antibody that warns T cells to activate and fight the tumor. The Hopkins scientists have dubbed these as “immunoswitch” nanoparticles since they effectively flip the immunity processes that would normally take place around tumor cells. The team tested the new approach on mice with melanoma and colon cancer, demonstrating much slower tumor growth, improved survival, and even full remission in up to half the mice studied. Study in journal ACS Nano: Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth… Via: American Chemical...
Vericred Offers Industry First Provider-Network Notification Service (Interview)

Vericred Offers Industry First Provider-Network Notification Service (Interview)

When providers transition amongst coverage networks, the results can be unexpected out-of-network bills to patients and an administrative burden on healthcare businesses managing coverage. Representing an important step forward in the trend towards increased transparency in healthcare, today, Vericred, based in New York City, is releasing a new offering in the form of provider-network notifications. Vericred, a healthcare data services company begun in 2014, made the announcement at this year’s AHIP Institute and EXPO event in New York City. The new capability provides value throughout “the lifecycle of a member’s enrollment in a health plan.” When members are looking for coverage, the service can help identify which providers are in-network or help a member find a plan for which their preferred provider is already in-network. Once on a plan, notifications can alert members if their provider leaves the network and help find a new one before the next time they need medical assistance. Members are not the only ones who may benefit from the new service. HR and benefits administration systems, private and public exchanges, health and wellness apps, and health insurance carriers are just some examples of  insurtech companies and services that may benefit from Vericred’s new service. Any organization using the service can register patients or members and tie those individuals to a list of providers. Anytime there is a change in Vericred’s provider-network data, alerts are sent to the organization, which can then take action such as sending a push notification or other alerts to individuals affected by the change. “Patients, providers and plans all benefit from proactive provider-network alerts. Creating a smart notification service is another step in our overarching mission to drive innovation in healthcare through...
Medtronic’s MiniMed 670G Hybrid Closed Loop Insulin Delivery System Now Available in U.S.

Medtronic’s MiniMed 670G Hybrid Closed Loop Insulin Delivery System Now Available in U.S.

Medtronic, having received FDA approval last year, is now introducing its MiniMed 670G hybrid closed loop insulin delivery system to the U.S. market. The first such system to become available, the MiniMed 670G utilizes Medtronic’s SmartGuard HCL algorithm to deduce when and how much insulin to deliver, yet allowing the patients themselves to make changes when necessary. The system’s most automated setting has it manage insulin delivery as long as the patient inputs carb counts after every meal, confirms any bolus changes, and periodically calibrates the sensor against a conventional finger prick glucometer, the CONTOUR NEXT LINK 2.4 from Ascensia Diabetes Care that comes with the system. The Guardian Sensor 3 within the package that measures glucose levels every five minutes can be worn continuously for up to a week, including during showering and other activities. It has a self-check feature that automatically helps keep the sensor accurate from measurement to measurement, helping to guarantee quality readings and therefore correct insulin delivery. From Medtronic: Data from the pivotal trial of the MiniMed 670G system published in the Journal of the American Medical Association (JAMA) demonstrated less glycemic variability, more time in the target range, less exposure to hypoglycemia and hyperglycemia, and reduced A1c for patients on the system.1 Importantly, real-world use of the system in the Customer Training Phase has shown consistent improved outcomes across several important areas including Time in Range (74 percent) and greater median time in Auto Mode (92 percent).2 Real-world use of the Guardian Sensor 3 also demonstrates continued strong performance and reliability of the company’s most accurate sensor to date with a MARD of 10.56 percent...
The Digital Health Update by Paul Sonnier ⋅ Jun 9, 2017 ⋅ #278

The Digital Health Update by Paul Sonnier ⋅ Jun 9, 2017 ⋅ #278

I made this announcement to 56,381 members of the Digital Health group on LinkedIn. If you’re on LinkedIn, please do join the group, which allows you to opt in to receiving these announcements in addition to connecting with thousands of other global stakeholders in digital health. Note that I will continue to update this announcement up until sending out the final version via LinkedIn. I’m also now using Constant Contact to send an html and image-rich version of my announcements. You can subscribe to that version here. The Digital Health Update by Paul Sonnier ⋅ Jun 9, 2017 ⋅ #278 Dear Group, As previously mentioned, I’m seeking a direct role with a company or organization that would, ideally, complement and leverage all that I’ve built and am doing, including my keynote speaking, weekly newsletter, Digital Health LinkedIn group, and contributing editor role at Innovation & Tech Today. My professional bio is viewable here. Please contact me if you see a potential fit or would like to advertise in my announcements, newsletter, and website. Please do not contact me with partnering or commission-type offers. I’ve published two issues of The Digital Health Newsletter since last week’s group announcement. I’ve copied and pasted the text from each newsletter below for better web-search (SEO) and archival purposes. The Digital Health Newsletter for June 2The Digital Health Newsletter for June 6 The Digital Health Newsletter for June 2 In their latest Internet Trends Report, Silicon Valley-based venture capital (VC) firm Kleiner Perkins Caufield & Byers (KPCB) and Mary Meeker have essentially corroborated my inclusion of genomics in the definition of digital health. A whopping seven pages in...
Edwards SAPIEN 3 Cardiac Valve FDA Approved for Mitral and Aortic Valve-in-Valve Procedures

Edwards SAPIEN 3 Cardiac Valve FDA Approved for Mitral and Aortic Valve-in-Valve Procedures

Edwards Lifesciences received FDA approval for its SAPIEN 3 transcatheter prosthetic heart valve to be used for valve-in-valve procedures. Indicated for placement within both the aortic and mitral valves in patients at risk of undergoing open heart surgery to remove an existing valve, the SAPIEN 3 can reside within a previously implanted bioprosthetic valve that has begun to fail. The device was previously approved in the U.S. for treatment of severe, symptomatic aortic stenosis in patients at high risk for open-heart surgery, as well as for patients that are at intermediate risk for open-heart surgery that would benefit from the SAPIEN 3. “This approval brings a safe and effective transcatheter therapy to patients who would do very poorly with repeat open-heart surgery,” said John Carroll, M.D., professor of cardiology at the University of Colorado School of Medicine and director of interventional cardiology at the University of Colorado Hospital, Denver and member of the TVT Registry Steering Committee. “I am pleased to see that the FDA recognizes the value of the high-quality evidence generated by the STS-ACC TVT Registry and its ability to play an important role in assessing ‘real-world’ clinical results in specialty indications, such as valve-in-valve, and for particular patient groups, such as those needing replacement of a bioprosthetic mitral valve.” Flashbacks: Edwards SAPIEN 3 Aortic Heart Valve Approved in U.S…; Edwards Sapien 3 Prosthetic Aortic Heart Valve Approved in Europe… Product page: Edwards SAPIEN 3 Transcatheter Heart Valve… Via:...
SandShark Anchor for Fixating Stimwave’s Neurostimulators Cleared in Europe

SandShark Anchor for Fixating Stimwave’s Neurostimulators Cleared in Europe

Most implantable neurostimulation systems consist of a pulse generator, that looks like a pacemaker, and electrode leads through which electric current is delivered. Stimwave Technologies out of Ft Lauderdale, Florida, has developed neurostimulation systems in which only the electrode component is implanted, while power is delivered wirelessly via a separate device placed against the skin near the implant. Now the company’s SandShark percutaneous injectable anchor system has been approved in Europe that helps to affix Stimwave’s implantable wireless neurostimulators within the target tissue. Implantation is a minimally invasive procedure that can be performed in an outpatient setting. It involves first injecting the stimulator, which is only a few millimeters long, and then sliding the SandShark over the implant and pushing it toward ligaments or other hard connective tissues. The anchor can be seen under X-ray fluoroscopy, and once in place, a mechanism is activated to open up the anchor’s wings so it’s locked in place. The orientation of the implant is preserved during the process, helping to make sure it’s aligned properly with the nearby target nerves. Flashback: Stimwave Freedom, World’s Smallest Neurostimulator, FDA Cleared for Back, Leg Pain… Via:...